All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Cao, 2020 0.15 [0.01; 3.29]
0.15 [0.01 ; 3.29 ] Cao, 2020 1 0% 41 NA not evaluable clinical deteriorationdetailed results Cao, 2020 0.11 [0.01; 2.21]
0.11 [0.01 ; 2.21 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvementdetailed results Cao, 2020 1.67 [0.84; 3.33]
1.67 [0.84 ; 3.33 ] Cao, 2020 1 0% 42 NA not evaluable clinical improvement (14-day)detailed results Cao, 2020 2.00 [0.58; 6.94]
2.00 [0.58 ; 6.94 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (21-day)detailed results Cao, 2020 1.50 [0.22; 10.08]
1.50 [0.22 ; 10.08 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (7-day)detailed results Cao, 2020 2.38 [0.38; 14.70]
2.38 [0.38 ; 14.70 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 1.67 [0.84; 3.33]
1.67 [0.84 ; 3.33 ] Cao, 2020 1 0% 42 NA not evaluable radiologic improvement (14-day)detailed results Cao, 2020 5.54 [1.01; 30.50]
5.54 [1.01 ; 30.50 ] Cao, 2020 1 0% 41 NA not evaluable serious adverse eventsdetailed results Cao, 2020 0.11 [0.01; 2.21]
0.11 [0.01 ; 2.21 ] Cao, 2020 1 0% 41 NA not evaluable adverse eventsdetailed results Cao, 2020 1.60 [0.38; 6.81]
1.60 [0.38 ; 6.81 ] Cao, 2020 1 0% 41 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-03 03:10 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290